

# Sharon M Moe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8886558/publications.pdf>

Version: 2024-02-01

237  
papers

16,975  
citations

17440

63  
h-index

15732

125  
g-index

240  
all docs

240  
docs citations

240  
times ranked

11084  
citing authors

#	ARTICLE	IF	CITATIONS
1	The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis. CKJ: Clinical Kidney Journal, 2022, 15, 136-144.	2.9	13
2	Reference data and calculators for second-generation HR-pQCT measures of the radius and tibia at anatomically standardized regions in White adults. Osteoporosis International, 2022, 33, 791-806.	3.1	16
3	<sc>Non-Additive</sc> Effects of Combined <sc>NOX1</sc>/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease-Mineral and Bone Disorder (<sc>CKD-MBD</sc>). JBMR Plus, 2022, 6, e10600.	2.7	2
4	Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease. Bone, 2022, 157, 116340.	2.9	7
5	Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease. Bone Reports, 2022, 16, 101174.	0.4	1
6	Vasopressin for Post-kidney Transplant Hypotension. Kidney International Reports, 2022, 7, 1364-1376.	0.8	2
7	Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. Kidney360, 2022, 3, 307-316.	2.1	9
8	<sc>Postdialysis</sc> serum phosphate equilibrium in hemodialysis patients on a controlled diet and no binders. Hemodialysis International, 2022, 26, 255-263.	0.9	2
9	Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD. Nephrology Dialysis Transplantation, 2022, 37, 1857-1867.	0.7	5
10	Genetic Variants Associated With Mineral Metabolism Traits in Chronic Kidney Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3866-e3876.	3.6	3
11	Initiation of Dialysis Is Associated With Impaired Cardiovascular Functional Capacity. Journal of the American Heart Association, 2022, 11, .	3.7	2
12	Spot Urine Samples to Estimate Na and K Intake in Patients With Chronic Kidney Disease and Healthy Adults: A Secondary Analysis From a Controlled Feeding Study. , 2021, 31, 602-610.		6
13	Plant-Based Diets, the Gut Microbiota, and Trimethylamine N-Oxide Production in Chronic Kidney Disease: Therapeutic Potential and Methodological Considerations. , 2021, 31, 121-131.		14
14	EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients. Kidney International, 2021, 99, 1225-1233.	5.2	26
15	Calciphylaxis or vascular oxalosis?. CKJ: Clinical Kidney Journal, 2021, 14, 435-438.	2.9	4
16	Reversing cortical porosity: Cortical pore infilling in preclinical models of chronic kidney disease. Bone, 2021, 143, 115632.	2.9	13
17	Advancing medical technology innovation and clinical translation via a model of industry-enabled technical and educational support: Indiana Clinical and Translational Sciences Institute's Medical Technology Advance Program. Journal of Clinical and Translational Science, 2021, 5, e79.	0.6	5
18	The Contribution of Known Familial Cardiovascular Disease Genes to Sudden Cardiac Death in Patients Undergoing Hemodialysis. CardioRenal Medicine, 2021, 11, 174-183.	1.9	0

#	ARTICLE	IF	CITATIONS
19	A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease. CKJ: Clinical Kidney Journal, 2021, 14, 1738-1746.	2.9	15
20	The cardiovascular“dialysis nexus: the transition to dialysis is a treacherous time for the heart. European Heart Journal, 2021, 42, 1244-1253.	2.2	14
21	Clinical, histopathologic and molecular features of idiopathic and diabetic nodular mesangial sclerosis in humans. Nephrology Dialysis Transplantation, 2021, 37, 72-84.	0.7	2
22	The impact of advanced glycation end products on bone properties in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2021, 30, 411-417.	2.0	7
23	Age and sex effects on FGF23-mediated response to mild phosphate challenge. Bone, 2021, 146, 115885.	2.9	19
24	Skeletal muscle metabolic responses to physical activity are muscle type specific in a rat model of chronic kidney disease. Scientific Reports, 2021, 11, 9788.	3.3	2
25	Intestinal Phosphorus Absorption in Moderate CKD and Healthy Adults Determined Using a Radioisotopic Tracer. Journal of the American Society of Nephrology: JASN, 2021, 32, 2057-2069.	6.1	17
26	High Moral Distress in Clinicians Involved in the Care of Undocumented Immigrants Needing Dialysis in the United States. Health Equity, 2021, 5, 484-492.	1.9	2
27	Regulation of reactive oxygen species in the pathogenesis of matrix vesicles induced calcification of recipient vascular smooth muscle cells. Vascular Medicine, 2021, 26, 585-594.	1.5	9
28	Single-cell RNA sequencing of intramedullary canal tissue to improve methods for studying fracture repair biology. BioTechniques, 2021, 71, 431-438.	1.8	1
29	Predicting fracture healing with blood biomarkers: the potential to assess patient risk of fracture nonunion. Biomarkers, 2021, 26, 703-717.	1.9	5
30	Feeling gutted in chronic kidney disease (CKD): Gastrointestinal disorders and therapies to improve gastrointestinal health in individuals CKD, including those undergoing dialysis. Seminars in Dialysis, 2021, , .	1.3	7
31	Skeletal and cardiovascular consequences of a positive calcium balance during hemodialysis. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2021, 43, 539-550.	0.9	3
32	Phosphate Binders and Nonphosphate Effects in the Gastrointestinal Tract. , 2020, 30, 4-10.		24
33	Kidney Disease Progression Does Not Decrease Intestinal Phosphorus Absorption in a Rat Model of Chronic Kidney Disease“Mineral Bone Disorder. Journal of Bone and Mineral Research, 2020, 35, 333-342.	2.8	14
34	Renal osteodystrophy and chronic kidney disease“mineral bone disorder. , 2020, , 1463-1487.		0
35	Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. CKJ: Clinical Kidney Journal, 2020, 13, 75-84.	2.9	20
36	Increasing Nephrologist Awareness of Symptom Burden in Older Hospitalized End-Stage Renal Disease Patients. American Journal of Nephrology, 2020, 51, 11-16.	3.1	8

#	ARTICLE	IF	CITATIONS
37	Effect of Advanced Glycation End-products (AGE) Lowering Drug ALT-711 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKD-MBD. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 608-617.	2.8	31
38	Using Spot Urine Samples to Estimate Sodium and Potassium intake in Healthy vs CKD Patients: Results from a Controlled Feeding Study. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa067_049.	0.3	0
39	An international cohort study of autosomal dominant tubulointerstitial kidney disease due to mutations identifies distinct clinical subtypes. <i>Kidney International</i> , 2020, 98, 1589-1604.	5.2	27
40	Cardiovascular Functional Changes in Chronic Kidney Disease: Integrative Physiology, Pathophysiology and Applications of Cardiopulmonary Exercise Testing. <i>Frontiers in Physiology</i> , 2020, 11, 572355.	2.8	18
41	Mobility Impairment in Patients New to Dialysis. <i>American Journal of Nephrology</i> , 2020, 51, 705-714.	3.1	10
42	4438 Twenty-four-hour Urinary Sodium Excretion Estimated from a Spot Urine Sample May Be Used as an Indicator of Intake in CKD Patients. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 40-41.	0.6	0
43	Prevalence and Persistence of Uremic Symptoms in Incident Dialysis Patients. <i>Kidney360</i> , 2020, 1, 86-92.	2.1	21
44	Adverse Effects of Autoclaved Diets on the Progression of Chronic Kidney Disease and Chronic Kidney Disease-Mineral Bone Disorder in Rats. <i>American Journal of Nephrology</i> , 2020, 51, 381-389.	3.1	4
45	N-acetylcysteine (NAC), an anti-oxidant, does not improve bone mechanical properties in a rat model of progressive chronic kidney disease-mineral bone disorder. <i>PLoS ONE</i> , 2020, 15, e0230379.	2.5	6
46	Kidney Histopathology and Prediction of Kidney Failure: A Retrospective Cohort Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 350-360.	1.9	38
47	A microRNA Approach to Discriminate Cortical Low Bone Turnover in Renal Osteodystrophy. <i>JBMR Plus</i> , 2020, 4, e10353.	2.7	12
48	Implementation of a Renal Precision Medicine Program: Clinician Attitudes and Acceptance. <i>Life</i> , 2020, 10, 32.	2.4	11
49	Title is missing!. , 2020, 15, e0230379.		0
50	Title is missing!. , 2020, 15, e0230379.		0
51	Title is missing!. , 2020, 15, e0230379.		0
52	Title is missing!. , 2020, 15, e0230379.		0
53	Calcimimetics Alter Periosteal and Perilacunar Bone Matrix Composition and Material Properties in Early Chronic Kidney Disease. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1297-1306.	2.8	8
54	Chronic kidney disease and peripheral nerve function in the Health, Aging and Body Composition Study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 625-632.	0.7	18

#	ARTICLE	IF	CITATIONS
55	Pilot Study of the Effects of High-Protein Meals During Hemodialysis on Intradialytic Hypotension in Patients Undergoing Maintenance Hemodialysis. , 2019, 29, 102-111.		21
56	Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing. Bone, 2019, 127, 419-426.	2.9	6
57	3318 Phosphorus Absorption in Healthy Adults and in Patients with Moderate Chronic Kidney Disease. Journal of Clinical and Translational Science, 2019, 3, 51-51.	0.6	0
58	Tester and testing procedure influence clinically determined gait speed. Gait and Posture, 2019, 74, 83-86.	1.4	14
59	Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis. American Journal of Nephrology, 2019, 49, 125-132.	3.1	9
60	Effect of ovariectomy on the progression of chronic kidney disease-mineral bone disorder (CKD-MBD) in female Cy/+ rats. Scientific Reports, 2019, 9, 7936.	3.3	14
61	Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study. Osteoporosis International, 2019, 30, 1693-1698.	3.1	4
62	Time course of rapid bone loss and cortical porosity formation observed by longitudinal $\mu$ CT in a rat model of CKD. Bone, 2019, 125, 16-24.	2.9	27
63	Comparison of Risk Factors for Pediatric Kidney Stone Formation: The Effects of Sex. Frontiers in Pediatrics, 2019, 7, 32.	1.9	11
64	Bone and Kidney. , 2019, , 375-386.		0
65	Voluntary Wheel Running Has Beneficial Effects in a Rat Model of CKD-Mineral Bone Disorder (CKD-MBD). Journal of the American Society of Nephrology: JASN, 2019, 30, 1898-1909.	6.1	9
66	Mineral Bone Disorders in Chronic Kidney Disease. , 2019, , 145-161.e6.		0
67	Characterizing Dysgeusia in Hemodialysis Patients. Chemical Senses, 2019, 44, 165-171.	2.0	21
68	Sudden cardiac death in patients undergoing dialysis: More than a single toxin. Heart Rhythm, 2019, 16, 318-319.	0.7	0
69	Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD. JCI Insight, 2019, 4, .	5.0	52
70	Rationale to reduce calcium intake in adult patients with chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2018, 27, 251-257.	2.0	12
71	Matrix vesicles induce calcification of recipient vascular smooth muscle cells through multiple signaling pathways. Kidney International, 2018, 93, 343-354.	5.2	88
72	Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Diseaseâ€“Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Annals of Internal Medicine, 2018, 168, 422.	3.9	228

#	ARTICLE	IF	CITATIONS
73	Effect of dietary phosphorus intake and age on intestinal phosphorus absorption efficiency and phosphorus balance in male rats. <i>PLoS ONE</i> , 2018, 13, e0207601.	2.5	14
74	Effects of treadmill running in a rat model of chronic kidney disease. <i>Biochemistry and Biophysics Reports</i> , 2018, 16, 19-23.	1.3	5
75	Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E594-E604.	3.5	30
76	Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2015-2027.	6.1	140
77	Skeletal vascular perfusion is altered in chronic kidney disease. <i>Bone Reports</i> , 2018, 8, 215-220.	0.4	3
78	Angiotensin-related genetic determinants of cardiovascular disease in patients undergoing hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2018, 34, 1924-1931.	0.7	5
79	Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease. <i>Osteoporosis International</i> , 2018, 29, 2139-2146.	3.1	8
80	GDF11 induces kidney fibrosis, renal cell epithelial-to-mesenchymal transition, and kidney dysfunction and failure. <i>Surgery</i> , 2018, 164, 262-273.	1.9	18
81	Twenty-Four-Hour Urine Phosphorus as a Biomarker of Dietary Phosphorus Intake and Absorption in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1002-1012.	4.5	24
82	Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 156.	7.4	213
83	Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 146.	7.4	122
84	Renal Osteodystrophy or Kidney-Induced Osteoporosis?. <i>Current Osteoporosis Reports</i> , 2017, 15, 194-197.	3.6	44
85	Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1128-1138.	4.5	21
86	Executive summary of the 2017 KDIGO Chronic Kidney Disease "Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. <i>Kidney International</i> , 2017, 92, 26-36.	5.2	698
87	A comparison between physicians and computer algorithms for form CMS 2728 data reporting. <i>Hemodialysis International</i> , 2017, 21, 117-124.	0.9	7
88	Moving Beyond the Assumed: Improving Fistula Success Rates. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2827-2829.	6.1	6
89	Calcium as a cardiovascular toxin in CKD-MBD. <i>Bone</i> , 2017, 100, 94-99.	2.9	33
90	Skeletal Muscle Regeneration and Oxidative Stress Are Altered in Chronic Kidney Disease. <i>PLoS ONE</i> , 2016, 11, e0159411.	2.5	62

#	ARTICLE	IF	CITATIONS
91	Calcium Homeostasis in Health and in Kidney Disease. , 2016, 6, 1781-1800.		38
92	Intracellular calcium increases in vascular smooth muscle cells with progression of chronic kidney disease in a rat model. Nephrology Dialysis Transplantation, 2016, 32, gfw274.	0.7	20
93	Fractures in Patients with CKD: Time for Action. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1929-1931.	4.5	72
94	Calcitriol Suppression of Parathyroid Hormone Fails to Improve Skeletal Properties in an Animal Model of Chronic Kidney Disease. American Journal of Nephrology, 2016, 43, 20-31.	3.1	7
95	Subcutaneous nerve activity and mechanisms of sudden death in a rat model of chronic kidney disease. Heart Rhythm, 2016, 13, 1105-1112.	0.7	11
96	Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 539-546.	4.5	20
97	Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease. Kidney International, 2016, 89, 95-104.	5.2	19
98	Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. American Journal of Kidney Diseases, 2016, 67, 559-566.	1.9	218
99	The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial. Journal of Human Hypertension, 2016, 30, 204-209.	2.2	13
100	Differential miRNA Expression in Cells and Matrix Vesicles in Vascular Smooth Muscle Cells from Rats with Kidney Disease. PLoS ONE, 2015, 10, e0131589.	2.5	37
101	The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 791-799.	4.5	75
102	Reduced skeletal muscle function is associated with decreased fiber cross-sectional area in the Cy/+ rat model of progressive kidney disease. Nephrology Dialysis Transplantation, 2015, 31, gfv352.	0.7	16
103	Bone marrow fat is increased in chronic kidney disease by magnetic resonance spectroscopy. Osteoporosis International, 2015, 26, 1801-1807.	3.1	24
104	Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease. Osteoporosis International, 2015, 26, 977-985.	3.1	35
105	Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis. Circulation, 2015, 132, 27-39.	1.6	259
106	Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions. Bone, 2015, 77, 50-56.	2.9	23
107	Pathophysiology of Vascular Calcification. Current Osteoporosis Reports, 2015, 13, 372-380.	3.6	83
108	ASN Presidential Address 2014: Moving Past Nephrology's Midlife Crisis. Journal of the American Society of Nephrology: JASN, 2015, 26, 791-795.	6.1	1

#	ARTICLE	IF	CITATIONS
109	Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1466-1475.	6.1	163
110	Anti-Sclerostin Antibody Treatment in a Rat Model of Progressive Renal Osteodystrophy. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 499-509.	2.8	103
111	Treating Bone Quality in Chronic Kidney Disease. <i>FASEB Journal</i> , 2015, 29, 702.1.	0.5	0
112	Assessment of $^{18}\text{F}$ -NaF Positron Emission Tomography Imaging for Early Coronary Artery Calcification. <i>FASEB Journal</i> , 2015, 29, 638.5.	0.5	2
113	A Comparison of Calcium to Zoledronic Acid for Improvement of Cortical Bone in an Animal Model of CKD. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 902-910.	2.8	72
114	The Effect of a Diet Containing 70% Protein from Plants on Mineral Metabolism and Musculoskeletal Health in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2014, 40, 582-591.	3.1	76
115	Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EVALUATION Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. <i>Journal of the American Heart Association</i> , 2014, 3, e001363.	3.7	105
116	Pathogenesis of Arrhythmias in a Model of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2812-2821.	6.1	34
117	Influence of Dietary Protein on Glomerular Filtration Before and After Bariatric Surgery: A Cohort Study. <i>American Journal of Kidney Diseases</i> , 2014, 63, 598-603.	1.9	14
118	Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium. <i>Bone</i> , 2014, 67, 139-144.	2.9	10
119	Adipocyte induced arterial calcification is prevented with sodium thiosulfate. <i>Biochemical and Biophysical Research Communications</i> , 2014, 449, 151-156.	2.1	61
120	Predicting the Glomerular Filtration Rate in Bariatric Surgery Patients. <i>American Journal of Nephrology</i> , 2014, 39, 8-15.	3.1	77
121	Cortical Bone Mechanical Properties Are Altered in an Animal Model of Progressive Chronic Kidney Disease. <i>PLoS ONE</i> , 2014, 9, e99262.	2.5	40
122	Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. <i>Osteoporosis International</i> , 2013, 24, 1471-1481.	3.1	37
123	Recent advances in the noninvasive diagnosis of renal osteodystrophy. <i>Kidney International</i> , 2013, 84, 886-894.	5.2	54
124	Transglutaminase 2 Accelerates Vascular Calcification in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2013, 37, 191-198.	3.1	35
125	The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4834-4844.	3.6	63
126	Rebuttal. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 321.	4.5	9



#	ARTICLE	IF	CITATIONS
127	What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 651-655.	2.0	14
128	Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. <i>Kidney International</i> , 2013, 83, 959-966.	5.2	205
129	The Case for Routine Parathyroid Hormone Monitoring. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 313-318.	4.5	32
130	Adverse Mandibular Bone Effects Associated with Kidney Disease Are Only Partially Corrected with Bisphosphonate and/or Calcium Treatment. <i>American Journal of Nephrology</i> , 2013, 38, 458-464.	3.1	10
131	Decreased MicroRNA Is Involved in the Vascular Remodeling Abnormalities in Chronic Kidney Disease (CKD). <i>PLoS ONE</i> , 2013, 8, e64558.	2.5	106
132	Reducing parathyroid hormone is essential for correcting cortical bone deficiencies associated with chronic kidney disease. <i>FASEB Journal</i> , 2013, 27, 967.10.	0.5	0
133	Comparing Mandated Health Care Reforms. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1535-1543.	4.5	31
134	Reimbursement of Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1291-1298.	6.1	121
135	Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2872-2879.	0.7	45
136	Klotho. <i>Circulation</i> , 2012, 125, 2181-2183.	1.6	52
137	Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2012, 367, 2482-2494.	27.0	805
138	Calcium Builds Strong Bones, and More Is Better—Correct? Well, Maybe Not. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1877-1883.	4.5	9
139	Chronic Kidney Disease-Mineral Bone Disorder: Definitions and Rationale for a Systemic Disorder. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2012, 10, 119-127.	0.8	3
140	Vascular Calcification: Pathophysiology and Risk Factors. <i>Current Hypertension Reports</i> , 2012, 14, 228-237.	3.5	150
141	Activation of Arterial Matrix Metalloproteinases Leads to Vascular Calcification in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2011, 34, 211-219.	3.1	76
142	Direct Effects of Phosphate on Vascular Cell Function. <i>Advances in Chronic Kidney Disease</i> , 2011, 18, 105-112.	1.4	103
143	The KDIGO guideline on dialysate calcium and patient outcomes: need for hard evidence. <i>Kidney International</i> , 2011, 79, 478.	5.2	10
144	Optimal vitamin D, calcitriol, and vitamin D analog replacement in chronic kidney disease: to D or not to D: that is the question. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 354-359.	2.0	20

#	ARTICLE	IF	CITATIONS
145	CKDâ€™Mineral and Bone Disorder: Core Curriculum 2011. American Journal of Kidney Diseases, 2011, 58, 1022-1036.	1.9	53
146	Children with chronic kidney disease: are they insured as adults?. Pediatric Nephrology, 2011, 26, 995-996.	1.7	1
147	The pathophysiology of early-stage chronic kidney diseaseâ€™mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. Journal of Bone and Mineral Research, 2011, 26, 2672-2681.	2.8	82
148	Vegetarian Compared with Meat Dietary Protein Source and Phosphorus Homeostasis in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 257-264.	4.5	440
149	Calcimimetics inhibit renal pathology in rodent nephronophthisis. Kidney International, 2011, 80, 612-619.	5.2	30
150	Efficacy of sodium thiosulfate for the treatment for calciphylaxis. Clinical Nephrology, 2011, 75, 485-490.	0.7	35
151	Chronic Kidney Disease-Mineral Bone Disorder. , 2011, , 2021-2058.		1
152	Confusion on the Complexity of Calcium Balance. Seminars in Dialysis, 2010, 23, 492-497.	1.3	22
153	A Randomized Trial of Cholecalciferol versus Doxercalciferol for Lowering Parathyroid Hormone in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 299-306.	4.5	67
154	Chronic Kidney Disease-Mineral Bone Disorder. , 2010, , 98-114.		5
155	RhoA/Rho kinase (ROCK) alters fetuin-A uptake and regulates calcification in bovine vascular smooth muscle cells (BVSMC). American Journal of Physiology - Renal Physiology, 2010, 299, F674-F680.	2.7	29
156	Hepatitis C Increases the Risk of Progression of Chronic Kidney Disease in Patients with Glomerulonephritis. American Journal of Nephrology, 2010, 32, 311-316.	3.1	27
157	Chronic kidney disease-mineral bone disorder (CKD-MBD). IBMS BoneKEy, 2010, 7, 447-457.	0.0	8
158	Verapamil inhibits calcification and matrix vesicle activity of bovine vascular smooth muscle cells. Kidney International, 2010, 77, 436-442.	5.2	51
159	Nephrolithiasis in the Wpk/+ Rats. FASEB Journal, 2010, 24, 1030.2.	0.5	0
160	Vascular Calcification: The Three-Hit Model. Journal of the American Society of Nephrology: JASN, 2009, 20, 1162.2-1164.	6.1	11
161	Calcimimetic Inhibits Late-Stage Cyst Growth in ADPKD. Journal of the American Society of Nephrology: JASN, 2009, 20, 1527-1532.	6.1	49
162	R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). Nephrology Dialysis Transplantation, 2009, 24, 2371-2377.	0.7	38

#	ARTICLE	IF	CITATIONS
163	A rat model of chronic kidney disease-mineral bone disorder. <i>Kidney International</i> , 2009, 75, 176-184.	5.2	136
164	Review article: Chronic kidney disease—mineral bone disorder: Have we got the assays right?. <i>Nephrology</i> , 2009, 14, 374-382.	1.6	13
165	Annexin-Mediated Matrix Vesicle Calcification in Vascular Smooth Muscle Cells. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1798-1805.	2.8	147
166	Variation in Serum and Plasma PTH Levels in Second-Generation Assays in Hemodialysis Patients: A Cross-sectional Study. <i>American Journal of Kidney Diseases</i> , 2008, 51, 987-995.	1.9	75
167	Association of Hepatitis C Virus Infection With Prevalence and Development of Kidney Disease. <i>American Journal of Kidney Diseases</i> , 2008, 51, 885-892.	1.9	50
168	Disorders Involving Calcium, Phosphorus, and Magnesium. <i>Primary Care - Clinics in Office Practice</i> , 2008, 35, 215-237.	1.6	249
169	Improving Global Outcomes in Mineral and Bone Disorders. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, S127-S130.	4.5	58
170	Precision of Biomarkers to Define Chronic Inflammation in CKD. <i>American Journal of Nephrology</i> , 2008, 28, 808-812.	3.1	12
171	Mechanisms of Vascular Calcification in Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 213-216.	6.1	443
172	Fetuin-A uptake in bovine vascular smooth muscle cells is calcium dependent and mediated by annexins. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, F599-F606.	2.7	55
173	Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients a pilot study. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3561-3567.	0.7	110
174	Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 898-905.	4.5	144
175	Management of Chronic Kidney Disease Mineral-Bone Disorder. <i>Advances in Chronic Kidney Disease</i> , 2007, 14, 44-53.	1.4	13
176	Chronic Kidney Disease—Mineral-Bone Disorder: A New Paradigm. <i>Advances in Chronic Kidney Disease</i> , 2007, 14, 3-12.	1.4	228
177	Management of Chronic Kidney Disease—Mineral Bone Disorder. <i>Advances in Chronic Kidney Disease</i> , 2007, 14, 2.	1.4	6
178	Vitamin D, Cardiovascular Disease, and Survival in Dialysis Patients. <i>Journal of Bone and Mineral Research</i> , 2007, 22, V95-V99.	2.8	8
179	Oral fish oil supplementation is efficacious and well tolerated in chronic hemodialysis patients: a pilot study. <i>FASEB Journal</i> , 2007, 21, A696.	0.5	0
180	Uremic Vascular Calcification. <i>Journal of Investigative Medicine</i> , 2006, 54, 380-384.	1.6	24

#	ARTICLE	IF	CITATIONS
181	Treatment of Chronic Kidney Disease-Mineral Bone Disorder and Vascular Complications. Therapeutic Apheresis and Dialysis, 2006, 10, S2-S15.	0.9	0
182	Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. European Journal of Clinical Investigation, 2006, 36, 51-62.	3.4	114
183	Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International, 2006, 69, 1945-1953.	5.2	1,586
184	The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells. Kidney International, 2006, 70, 1046-1053.	5.2	116
185	Vascular calcification: Hardening of the evidence. Kidney International, 2006, 70, 1535-1537.	5.2	18
186	Fish Consumption and Omega-3 Fatty Acid Status and Determinants in Long-Term Hemodialysis. American Journal of Kidney Diseases, 2006, 47, 1064-1071.	1.9	71
187	High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells. Nephrology Dialysis Transplantation, 2006, 21, 3435-3442.	0.7	159
188	The Case against Calcium-Based Phosphate Binders. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 697-703.	4.5	89
189	Review of the Effects of Omega-3 Supplementation in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 182-192.	4.5	115
190	Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease. Circulation, 2006, 114, 1083-1087.	1.6	302
191	Omega-3 PUFA plasma and red blood cell status in chronic hemodialysis patients. FASEB Journal, 2006, 20, A183.	0.5	0
192	Disorders of Phosphorous Homeostasis in CKD. , 2006, , 13-28.		0
193	VITAMIN D IN HEALTH AND DISEASE: The Role of Vitamin D in Vascular Calcification in Chronic Kidney Disease. Seminars in Dialysis, 2005, 18, 307-314.	1.3	50
194	Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney International, 2005, 67, 2295-2304.	5.2	321
195	Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney International, 2005, 67, 760-771.	5.2	290
196	Disorders of calcium, phosphorus, and magnesium. American Journal of Kidney Diseases, 2005, 45, 213-218.	1.9	22
197	Prevalence of Calcidiol Deficiency in CKD: A Cross-Sectional Study Across Latitudes in the United States. American Journal of Kidney Diseases, 2005, 45, 1026-1033.	1.9	346
198	Calcification or Classification?. Journal of the American Society of Nephrology: JASN, 2005, 16, 293-295.	6.1	14

#	ARTICLE	IF	CITATIONS
199	Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2186-2193.	0.7	135
200	Inflammation and Vascular Calcification. <i>Blood Purification</i> , 2005, 23, 64-71.	1.8	102
201	Cinacalcet Hydrochloride. <i>Drugs</i> , 2005, 65, 282-283.	10.9	1
202	Management of Renal Osteodystrophy in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2004, 24, 209-216.	2.3	23
203	Natural history of vascular calcification in dialysis and transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2387-2393.	0.7	150
204	Pathophysiology of Vascular Calcification in Chronic Kidney Disease. <i>Circulation Research</i> , 2004, 95, 560-567.	4.5	440
205	Uremic vasculopathy. <i>Seminars in Nephrology</i> , 2004, 24, 413-416.	1.6	15
206	Vascular calcification in chronic kidney disease. <i>Seminars in Nephrology</i> , 2004, 24, 61-68.	1.6	48
207	Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. <i>New England Journal of Medicine</i> , 2004, 350, 1516-1525.	27.0	1,023
208	Management of renal osteodystrophy in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2004, 24, 209-16.	2.3	7
209	Arterial calcification in diabetes. <i>Current Diabetes Reports</i> , 2003, 3, 28-32.	4.2	142
210	Calciophylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis. <i>Pediatric Nephrology</i> , 2003, 18, 969-975.	1.7	62
211	Vascular calcification in dialysis patients: Pathogenesis and consequences. <i>American Journal of Kidney Diseases</i> , 2003, 41, S96-S99.	1.9	73
212	Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. <i>American Journal of Kidney Diseases</i> , 2003, 42, 1253-1259.	1.9	73
213	Identity and localization of advanced glycation end products on human $\beta$ 2-microglobulin using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. <i>Analytical Biochemistry</i> , 2003, 314, 322-325.	2.4	12
214	The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. <i>Kidney International</i> , 2003, 63, 248-254.	5.2	216
215	Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. <i>Kidney International</i> , 2003, 63, 1003-1011.	5.2	289
216	Assessment of vascular calcification in ESRD patients using spiral CT. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1152-1158.	0.7	145

#	ARTICLE	IF	CITATIONS
217	Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product. <i>American Journal of Nephrology</i> , 2003, 23, 369-379.	3.1	115
218	Signal transduction of $\hat{1}^{25}$ OH-vitamin D-induced expression of VCAM-1 and COX-2 in synovial fibroblasts. <i>Kidney International</i> , 2002, 61, 414-424.	5.2	23
219	Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. <i>Kidney International</i> , 2002, 61, 638-647.	5.2	387
220	Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. <i>Kidney International</i> , 2002, 62, 1724-1731.	5.2	297
221	Distal calcific uremic arteriopathy in a hemodialysis patient responds to lowering of Ca P product and aggressive wound care. <i>Clinical Nephrology</i> , 2002, 58, 238-243.	0.7	56
222	[Vascular calcification in end stage renal disease]. <i>Clinical Calcium</i> , 2002, 12, 1417-22.	0.2	5
223	Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. <i>American Journal of Kidney Diseases</i> , 2001, 37, 1267-1276.	1.9	210
224	Current Issues in the Management of Secondary Hyperparathyroidism and Bone Disease. <i>Peritoneal Dialysis International</i> , 2001, 21, 241-246.	2.3	10
225	$\hat{1}^{25}$ -Microglobulin increases the expression of vascular cell adhesion molecule on human synovial fibroblasts. <i>Kidney International</i> , 2001, 59, 1951-1959.	5.2	13
226	The Role of the Synovium and Cartilage in the Pathogenesis of $\hat{1}^{25}$ -Microglobulin-Related Amyloidosis. <i>Seminars in Dialysis</i> , 2001, 14, 127-130.	1.3	17
227	A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. <i>American Journal of Kidney Diseases</i> , 2001, 38, 792-802.	1.9	45
228	Current issues in the management of secondary hyperparathyroidism and bone disease. <i>Peritoneal Dialysis International</i> , 2001, 21 Suppl 3, S241-6.	2.3	5
229	$\hat{1}^{25}$ -microglobulin induces MMP-1 but not TIMP-1 expression in human synovial fibroblasts. <i>Kidney International</i> , 2000, 57, 2023-2034.	5.2	37
230	A coculture model of synoviocytes and bone for the evaluation of potential arthritis therapies. <i>Journal of Pharmacological and Toxicological Methods</i> , 1999, 41, 127-134.	0.7	1
231	Osteoporosis in end-state renal disease. <i>Seminars in Nephrology</i> , 1999, 19, 115-22.	1.6	85
232	The treatment of steroid-induced bone loss in transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 1997, 6, 544-549.	2.0	15
233	Clinical Manifestations and Pathogenesis of Dialysis-Related Amyloidosis. <i>Seminars in Dialysis</i> , 1996, 9, 360-368.	1.3	23
234	Role of IL-1 $\hat{1}$ and prostaglandins in $\hat{1}^{25}$ -microglobulin-induced bone mineral dissolution. <i>Kidney International</i> , 1995, 47, 587-591.	5.2	23

#	ARTICLE	IF	CITATIONS
235	Uremic encephalopathy. <i>Clinical Nephrology</i> , 1994, 42, 251-6.	0.7	40
236	Maintenance of Bone Mass in Patients Receiving Dialytic Therapy. <i>American Journal of Kidney Diseases</i> , 1993, 22, 300-307.	1.9	29
237	Safety and Efficacy of Long-Term Treatment of Secondary Hyperparathyroidism by Low-Dose Intravenous Calcitriol. <i>American Journal of Kidney Diseases</i> , 1992, 19, 532-539.	1.9	40